October 7, 2026
They called it a 37% premium. Shareholders who held from January got a discount.
Hey there, bargain hunter. Option Care Health spent most of 2026 being ignored. The stock hit $36.80 in January, got crushed about 24% on a weak Q1 earnings report in April, spent the summer drifting in the low $20s, and closed October 5 at $23.37. Then Tuesday morning arrived.
J.P. Morgan Is Building on This Under-$1 Crypto
While fear hits levels not seen since 2022, major institutions aren’t backing off – they’re building. One little-known crypto is being used for real infrastructure tied to moving traditional assets on-chain. With supply tightening and activity expected to rise, this setup is getting harder to ignore.
Get the full breakdown on this under-$1 crypto before attention grows
Scoreboard
OPCH surged 34% intraday after CD&R and McKesson announced a definitive agreement to acquire the company for $32.05 per share in cash, implying a total enterprise value of approximately $5.8 billion including debt. The offer represents a 37% premium to OPCH’s October 5 closing price. Shares settled near $31 by end of day. McKesson will invest roughly $1.4 billion for a 49% stake, with CD&R holding the majority 51%. Closing is expected in the first half of 2027, pending shareholder and regulatory approvals.
The Real Reason
The 37% premium sounds generous until you remember where OPCH was trading nine months ago. At $32.05, CD&R and McKesson are paying $4.75 below the 52-week high of $36.80, set in January. Public shareholders who panicked after the Q1 miss and sold in the low $20s handed this deal to two sophisticated buyers at a steep discount to where the stock had been, and arguably where the business was heading anyway.
The Q1 miss was real: revenue of $1.35 billion grew just 1.3% year over year, while adjusted EBITDA dropped 6% to $104.8 million on headwinds from the chronic inflammatory disease portfolio. Management cut full-year revenue guidance from a range of $5.8 billion to $6.0 billion to $5.675 billion to $5.775 billion. The market punished the stock by about 24% in a single session. That punishment is what created this deal.
What the Business Actually Does
Option Care Health is the nation’s largest independent provider of home and alternate-site infusion services, operating through 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers complex therapies, including anti-infectives, immunoglobulin, nutrition support, and specialty biologics, outside hospital settings. Revenue has grown from about $3.0 billion in 2020 to $5.65 billion in 2025.
The Energy Stock Trump Once Called “A Big Mistake” to Mess With
When a U.S. ally tried to tax ONE American energy company…
Trump didn’t hesitate to issue a direct warning.
Now this same company is generating over $3 billion in operating income…
And partnering with the hottest AI stock on Wall Street.
Out of 23,281 publicly traded stocks, this is the ONLY one that meets all the “unicorn” criteria.
For McKesson, this is a strategic expansion into specialty pharmaceutical delivery beyond the distributor role. The deal gives McKesson a national clinical platform for rare disease and orphan drug therapies. The transaction also establishes a framework for McKesson to eventually acquire CD&R’s 51% stake outright, subject to conditions and regulatory approval. Day one, McKesson accounts for the investment under the equity method. Full consolidation comes later, if it comes at all.
Data Check
- Q2 2026 revenue: $1.44 billion, up 1.9% year over year; adjusted EBITDA of $117.5 million, up 3%
- Full-year 2026 guidance (withdrawn upon deal announcement): revenue of $5.675 to $5.775 billion; adjusted EBITDA of $480 to $495 million
- Q2 operating cash flow: $184 million; net debt to EBITDA: not disclosed in the earnings release
- $32.05 acquisition price represents roughly 11.8x the midpoint of 2026 EBITDA guidance
- Deal financing committed by Bank of America, Barclays, Goldman Sachs, Jefferies, and Wells Fargo
Is It Cheap?
At roughly 11.8x EBITDA, this is not an expensive deal for a business guiding to $480 million or more in annual adjusted EBITDA with cash flow from operations of at least $320 million. Home infusion is a durable, recurring-revenue model with demographic tailwinds. The CID headwinds that cratered the stock were real but arguably temporary, linked to patient census resets and therapy mix shifts rather than structural demand destruction. CD&R and McKesson are buying at a moment of maximum pessimism from public holders. That is not an accident.
Bull / Base / Bear
Bull: McKesson eventually acquires CD&R’s stake at a premium to $32.05, making the takeout price look conservative in hindsight. Home infusion volumes recover, EBITDA approaches $500 million, and the strategic value justifies a higher full buyout.
Base: Deal closes in H1 2027 at $32.05 as agreed. OPCH shareholders collect their cash and redeploy elsewhere. McKesson builds out the platform quietly before deciding on full consolidation.
Oil Just Crossed $100 – Here’s Why It Matters
Ships seized. Supply routes disrupted.
Nearly 20% of global oil flows through one chokepoint – and it’s under pressure.
While prices swing, there’s a way to collect income as oil moves.
Bear: Regulatory friction or a shareholder vote rejection delays or derails the deal. Shares revert toward pre-announcement levels in the low $20s. At that point the business fundamentals, not the deal, have to carry the load.
Action Plan
OPCH is now essentially a closed arbitrage. Shares are trading near $31, against a deal price of $32.05 with an expected close in H1 2027. That spread implies a modest annualized return, appropriate only for investors with tolerance for deal-break risk. There is no compelling reason to buy here unless you are running a merger-arb book. For everyone else, the trade was in the $20s, and that window closed Tuesday morning.
Cheap Investor Checklist
- Deal price vs. 52-week high: $32.05 vs. $36.80. Sellers left money on the table.
- EBITDA multiple: approximately 11.8x. Reasonable for a durable, recurring-revenue healthcare platform.
- McKesson buyout framework: optionality for full consolidation embedded in the structure.
- Financing: five major banks committed. Execution risk is low.
- Q2 momentum: revenue, EBITDA, and EPS all beat estimates after the Q1 miss. The business was stabilizing.
- Regulatory risk: specialty pharma distribution plus home infusion under one roof may attract scrutiny.
- Shareholder vote: unanimously approved by OPCH board. No activist opposition yet.
- Timeline: H1 2027 close expected. Roughly six to nine months of hold for arb players.
Bottom Line
If the deal closes at $32.05, CD&R and McKesson bought one of healthcare’s most durable recurring-revenue platforms at a price that public shareholders had already seen at $36.80 earlier this year. The 37% premium felt generous to a market that panicked in April. In two or three years, if McKesson exercises its option to take the rest, $32.05 will probably look like the real bargain in this transaction.
